Results

Horizon Therapeutics plc

06/24/2022 | Press release | Distributed by Public on 06/24/2022 10:33

New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)